- Home
- YRD vs NTHI Comparison
YRD vs NTHI Comparison
Compare YRD & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | YRD | NTHI |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | China | United States |
| Employees | N/A | 5 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.4M | 93.9M |
| IPO Year | 2015 | 2023 |
Fundamental Metrics
Financial Performance| Metric | YRD | NTHI |
|---|---|---|
| Price | $1.00 | $3.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 48.2K | ★ 256.1K |
| Earning Date | 06-11-2026 | 05-19-2026 |
| Dividend Yield | ★ 23.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.86 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.82 | $3.01 |
| 52 Week High | $6.79 | $12.99 |
Technical Indicators
Market Signals| Indicator | YRD | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 36.21 | 40.35 |
| Support Level | $0.82 | $3.07 |
| Resistance Level | $1.29 | $3.70 |
| Average True Range (ATR) | 0.06 | 0.45 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 14.08 | 10.66 |
Price Performance
Historical ComparisonAbout YRD Yiren Digital Ltd.
Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.